On This Day in Health: June 12, 2025
On June 12, 2025, the U.S. Food and Drug Administration approved a new role for Merck's pembrolizumab, sold as Keytruda, in treating certain head and neck cancers in the United States. The authorization placed the immunotherapy both before and after surgery for adults with resectable, locally advanced head and neck squamous cell carcinoma whose tumors met a specified PD-L1 test threshold. It was the first FDA approval of a perioperative treatment regimen for this setting. The change brought an established immune checkpoint medicine into an earlier stage of care, alongside a treatment plan that continued to depend on surgery and postoperative therapy.
Locally advanced disease can remain difficult to control even when a surgeon can remove the visible tumor. Treatment has commonly combined surgery with radiation, adding cisplatin for patients whose surgical findings indicate higher risk. Pembrolizumab had already become important for recurrent or metastatic head and neck cancer. The new question was whether giving it around the time of an operation could improve outcomes before a recurrence occurred. As an anti-PD-1 antibody, the medicine helps counter an immune checkpoint that can limit the body's response to cancer. Moving that approach earlier required evidence from a study designed for patients whose tumors were still considered removable.
The KEYNOTE-689 trial randomly assigned 714 patients to standard care with or without perioperative pembrolizumab. The experimental sequence began with pembrolizumab before surgery, followed by the medicine with radiation, with or without cisplatin, and then pembrolizumab alone. The main measure was event-free survival, which included progression preventing definitive surgery, later progression or recurrence, and death. In the group with a PD-L1 combined positive score of at least one, the median was 59.7 months with the pembrolizumab regimen and 29.6 months with standard care alone. That comparison concerned the time to a defined set of events. It did not mean that treatment doubled every patient's lifespan or guaranteed that the cancer would never return.
The June authorization had clear limits. It applied to a specified cancer type, stage, surgical setting and biomarker-defined population, rather than all head and neck tumors. Overall-survival results were still immature at the analysis supporting approval. Immune-mediated and infusion-related adverse reactions remained important safety considerations, and the extra treatment required coordination before and after an operation. The decision nevertheless expanded the options available within a curative-intent treatment pathway. Its historical importance lies in the change of timing: an immunotherapy already used for later disease gained an authorized place around surgery. The milestone reflects a broader effort to prevent recurrence earlier, while retaining the careful patient selection and combined local treatment that the evidence supported.
Perioperative treatment spans the period before and after surgery. Neoadjuvant therapy comes before an operation; adjuvant therapy follows it.
The authorization required a PD-L1 combined positive score of at least one, measured with an FDA-approved test.
KEYNOTE-689 compared standard care alone with a sequence adding pembrolizumab around surgery and postoperative radiation-based therapy.
Event-free survival includes several outcomes. It should not be described as the same thing as overall survival or permanent cure.
The decision extended checkpoint immunotherapy into an earlier treatment setting for selected resectable head and neck cancers.
Surgery, postoperative risk assessment and coordinated care remained essential; the new medicine did not remove those parts of treatment.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.